BioMarin Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $119 at Deutsche Bank
August 3, 2017 8:52 AM EDTDeutsche Bank raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $119.00 (from $118.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Todays results and hemophilia update continue to support our bullish view on BioMarins diversified and high-growth portfolio. Second quarter... More
BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
August 2, 2017 4:27 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More